A Double Blind Randomized Controlled Trial of Dihydroartemisinin-piperaquine Alone and in Combination With Single Dose Primaquine to Reduce Post-treatment Malaria Transmission.
Phase of Trial: Phase III
Latest Information Update: 29 Jan 2016
Price : $35 *
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary) ; Primaquine
- Indications Malaria
- Focus Therapeutic Use
- Acronyms DAPPI
- 13 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 31 Mar 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015, according to to ClinicalTrials.gov record.
- 31 Mar 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Sep 2015, according to to ClinicalTrials.gov record.